Question 1

What does ketamine therapy do in the brain?

Accepted Answer

Ketamine therapy (including esketamine/Spravato) temporarily shifts glutamate signaling — the brain’s primary “go” system — helping neurons communicate more effectively and opening a short neuroplasticity window for mood relief and cognitive flexibility.  [oai_citation:0‡Neuroscience Writeups.docx](file-service://file-3dVZT9WrXt4XNB9pPckt94)

Question 2

How does Spravato (esketamine) relate to ketamine treatment?

Accepted Answer

Spravato is the FDA-approved intranasal form of esketamine (the S-enantiomer of ketamine). It acts on the same core glutamate pathway as ketamine but is delivered in a standardized, in-clinic protocol that many insurers cover.

Question 3

Does ketamine or esketamine increase neuroplasticity?

Accepted Answer

Yes. Both ketamine and esketamine trigger downstream changes (including BDNF activity) that support new synaptic connections; this is why the hours to days after dosing can be an especially helpful time for change.

Question 4

Why is glutamate important for ketamine therapy for depression?

Accepted Answer

Glutamate is the brain’s main excitatory signal — the “green light” that moves information forward. Ketamine therapy modulates this system, which may help restore flexible thinking and mood regulation when depression has made signals feel stuck.

Question 5

How does ketamine affect GABA, the brain’s calming system?

Accepted Answer

Ketamine’s NMDA-related effects on glutamate can loosen inhibitory feedback on GABAergic interneurons, briefly rebalancing excitation and inhibition — a shift linked to rapid antidepressant effects in ketamine treatment.

Question 6

What does ketamine treatment feel like during a session?

Accepted Answer

Many patients describe a gentle dissociation — feeling more spacious, observing thoughts with less rigidity, sometimes with vivid imagery — which can make entrenched depressive loops feel quieter for a time.

Question 7

How quickly can ketamine or Spravato work for depression?

Accepted Answer

Some people notice improvement within the first day; others improve over several sessions. In clinical narratives and protocols, early responders within the first 1–2 weeks are common with ketamine therapy and Spravato treatment.

Question 8

How long do benefits from ketamine therapy last?

Accepted Answer

Benefits can last days to weeks after a dose; most patients follow an induction and maintenance plan so that repeated sessions reinforce more durable relief during the neuroplasticity window.

Question 9

Is ketamine therapy safe, including Spravato treatment?

Accepted Answer

When delivered in a certified clinic with screening and monitoring, ketamine and Spravato are considered safe for many patients; short-lived effects like nausea, dizziness, or dissociation are commonly observed and supported on-site.

Question 10

What are the long-term risks of ketamine or esketamine?

Accepted Answer

Therapeutic dosing has not been shown to cause long-term cognitive decline; rare risks include urinary or cardiovascular issues, which are monitored in clinical care plans during ketamine treatment and Spravato protocols.

Question 11

Can ketamine or Spravato be addictive?

Accepted Answer

While ketamine has known misuse potential in unsupervised settings, clinic-based ketamine therapy and Spravato follow controlled dosing with medical oversight, which keeps the risk of dependence low.

Question 12

Who is not a good candidate for ketamine or Spravato?

Accepted Answer

Active psychosis, uncontrolled hypertension or significant cardiac disease, pregnancy, and unstable substance use are common reasons to defer ketamine treatment; careful screening aligns safety with patient goals.

Question 13

How does ketamine compare with traditional antidepressants for depression?

Accepted Answer

SSRIs act primarily on serotonin and often take weeks. Ketamine and esketamine act on glutamate, producing faster changes in mood and cognitive flexibility for some patients with treatment-resistant depression.

Question 14

What’s the difference between off-label ketamine and Spravato (esketamine) treatment?

Accepted Answer

Both use the same core mechanism; the differences are regulatory and logistical. Off-label ketamine (often IV/IM) is not FDA-approved for depression and may not be covered; Spravato is FDA-approved intranasal esketamine with a standardized, insurance-supported protocol.

Question 15

Why is Spravato delivered as a nasal spray?

Accepted Answer

Spravato’s low-volume, high-concentration intranasal design optimizes mucosal absorption and dosing fidelity, supporting predictable effects, on-site monitoring, FDA approval, and insurance coverage.

Question 16

How can I make the most of ketamine or Spravato treatment?

Accepted Answer

Plan simple, supportive actions during the first ~72 hours after dosing — e.g., therapy, journaling, or small behavioral goals. This aligns with the neuroplasticity window so new patterns are more likely to stick.

HEALING STARTS HERE

Ketamine in the Brain: The Neuroscience Explained

Ketamine and Spravato (esketamine) have similar & powerful mechanisms of action

Insurance-covered Spravato (esketamine) treatment in Boston

The science behind ketamine: how ketamine works in the brain

Frequently Asked Questions

VIP experience from the Lumin Health team of experts in ketamine treatment

Take the first step — contact Lumin Health today